Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shandong Weigao Group Medical Polymer Co ( (HK:1066) ).
Shandong Weigao Group Medical Polymer reported unaudited revenue of about RMB3.35 billion for the first quarter of 2026, representing year-on-year growth of roughly 5.3%. The company said medical devices and pharma packaging delivered high single-digit gains, while orthopaedic and interventional businesses grew modestly and blood management revenue declined mid-single digits.
Management highlighted that growth was uneven across its portfolio, underscoring the relative resilience of device and packaging demand versus pressure in blood management. The update, based on unaudited figures, signals steady expansion but also points to segmental challenges that shareholders and potential investors are urged to weigh carefully when assessing the group’s performance and outlook.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a PRC-based medical device manufacturer focused on polymer-based products and related healthcare solutions. The group operates across medical devices, pharma packaging, orthopaedics, interventional products and blood management, serving hospital and clinical markets in China and abroad.
Average Trading Volume: 21,938,675
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.6B
Find detailed analytics on 1066 stock on TipRanks’ Stock Analysis page.